Investigation into the optimal dosage of cyclooxygenase-1 inhibitors based on an antiplatelet effect for Kawasaki disease

Research Project

Project/Area Number	25460223
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Medical pharmacy
Research Institution	Tokyo University of Pharmacy and Life Science
Principal Investigator	Yokoyama Haruko 東京薬科大学, 薬学部, 講師 (80385509)
Project Period (FY)	2013-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords	抗血小板作用 / COX-1 / 投与設計 / 川崎病
Outline of Final Research Achievements	The aim of the present study was to establish a dosage regimen for exerting an appropriate antiplatelet effect after administration of flurbiprofen based on the antiplatelet effect of aspirin in Kawasaki disease. When a usual dosage per time which described in the Kawasaki disease guidelines, was administered orally more than twice per day, the sufficient antiplatelet effect was shown. Furthermore, it was able to establish the methodology to exert the antiplatelet effect of flurbiprofen, which was administered orally and/or percutaneously in children.

Report

(4 results)